AZR-MD-001, under investigation for the treatment of contact lens discomfort, has reached the primary endpoints in the phase 2 ECLIPTIC study, according to a press release from Azura Ophthalmics.
Topline results from the single-center, single-masked, vehicle-controlled, randomized, parallel-group study showed 26 participants treated with twice-weekly AZR-MD-001 (selenium disulfide), applied to the lower lid margin, had significantly improved meibum gland secretion scores after 14 days (mean score improvement, 3.4; P < .05), with improvement continuing until the end of the study (mean score
Uncategorized